JP7339955B2 - 安定したアスコルビン酸組成物およびそれを使用する方法 - Google Patents

安定したアスコルビン酸組成物およびそれを使用する方法 Download PDF

Info

Publication number
JP7339955B2
JP7339955B2 JP2020545050A JP2020545050A JP7339955B2 JP 7339955 B2 JP7339955 B2 JP 7339955B2 JP 2020545050 A JP2020545050 A JP 2020545050A JP 2020545050 A JP2020545050 A JP 2020545050A JP 7339955 B2 JP7339955 B2 JP 7339955B2
Authority
JP
Japan
Prior art keywords
composition
subject
less
glutathione
airway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020545050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503497A5 (enExample
JP2021503497A (ja
Inventor
ダン コペランド
キャロライン ダラム
Original Assignee
レノビオン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レノビオン インコーポレイテッド filed Critical レノビオン インコーポレイテッド
Publication of JP2021503497A publication Critical patent/JP2021503497A/ja
Publication of JP2021503497A5 publication Critical patent/JP2021503497A5/ja
Priority to JP2023090905A priority Critical patent/JP7617179B2/ja
Application granted granted Critical
Publication of JP7339955B2 publication Critical patent/JP7339955B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020545050A 2017-11-17 2018-11-16 安定したアスコルビン酸組成物およびそれを使用する方法 Active JP7339955B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023090905A JP7617179B2 (ja) 2017-11-17 2023-06-01 安定したアスコルビン酸組成物およびそれを使用する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762588300P 2017-11-17 2017-11-17
US62/588,300 2017-11-17
US201862684700P 2018-06-13 2018-06-13
US62/684,700 2018-06-13
PCT/US2018/061686 WO2019099946A1 (en) 2017-11-17 2018-11-16 Stable ascorbic acid compositions and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023090905A Division JP7617179B2 (ja) 2017-11-17 2023-06-01 安定したアスコルビン酸組成物およびそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2021503497A JP2021503497A (ja) 2021-02-12
JP2021503497A5 JP2021503497A5 (enExample) 2021-12-23
JP7339955B2 true JP7339955B2 (ja) 2023-09-06

Family

ID=66539933

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020545050A Active JP7339955B2 (ja) 2017-11-17 2018-11-16 安定したアスコルビン酸組成物およびそれを使用する方法
JP2023090905A Active JP7617179B2 (ja) 2017-11-17 2023-06-01 安定したアスコルビン酸組成物およびそれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023090905A Active JP7617179B2 (ja) 2017-11-17 2023-06-01 安定したアスコルビン酸組成物およびそれを使用する方法

Country Status (22)

Country Link
US (4) US11497786B2 (enExample)
EP (2) EP4473976A3 (enExample)
JP (2) JP7339955B2 (enExample)
KR (1) KR102731292B1 (enExample)
CN (1) CN111615395B (enExample)
AU (2) AU2018367674B2 (enExample)
BR (1) BR112020009910A2 (enExample)
CA (1) CA3082900A1 (enExample)
DK (1) DK3710036T3 (enExample)
ES (1) ES3008699T3 (enExample)
FI (1) FI3710036T3 (enExample)
HR (1) HRP20241746T1 (enExample)
HU (1) HUE069510T2 (enExample)
IL (1) IL274635B2 (enExample)
LT (1) LT3710036T (enExample)
MX (2) MX2020005087A (enExample)
PH (1) PH12020550645A1 (enExample)
PL (1) PL3710036T3 (enExample)
PT (1) PT3710036T (enExample)
SG (1) SG11202004540QA (enExample)
SI (1) SI3710036T1 (enExample)
WO (1) WO2019099946A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230117644A (ko) 2016-11-17 2023-08-08 레노비온, 아이엔씨. 글루타티온 조성물에 의한 호흡기 질환 및 감염 치료
ES3008699T3 (en) 2017-11-17 2025-03-24 Renovion Inc Stable ascorbic acid compositions and methods of using the same
CN111413492A (zh) * 2020-04-30 2020-07-14 山东大学 一种用于检测新型冠状病毒covid-2019肺炎的方法及系统
EP3970718A1 (en) * 2020-09-18 2022-03-23 Charité - Universitätsmedizin Berlin New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators
US20240337645A1 (en) * 2021-08-04 2024-10-10 The Trustees Of Indiana University Methods of treating compromised lung function and assessing clinical improvement
CN113995744B (zh) * 2021-10-13 2023-03-17 温州肯恩大学 一种组合物及其抗菌应用
IL313997A (en) 2022-01-04 2024-08-01 Renovion Inc Aqueous solution including glutathione salt
WO2023141237A1 (en) * 2022-01-20 2023-07-27 Cell and Molecular Tissue Engineering, LLC Methods and products to detect, minimize and treat trap-related tissue reactions and tissue injury associated with medical devices
WO2024016019A1 (en) * 2022-07-15 2024-01-18 Renovion, Inc. Compositions and methods for treatment of subjects suffering from a sars-cov-2 infection
WO2025231041A1 (en) * 2024-04-30 2025-11-06 Renovion, Inc. Methods for reducing symptoms in subjects suffering from bronchiectasis and other pulmonary diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002004A1 (en) 1999-07-02 2001-01-11 Lee Hibahl Peritoneal dialysis solution containing antioxidant for treating renal failure
US20100311837A1 (en) 2008-02-05 2010-12-09 Kyowa Hakko Bio Co., Ltd. Method for improving storage stability of glutathione
US20150010654A1 (en) 2012-10-29 2015-01-08 The University Of North Carolina At Chapel Hill Methods and Compositions for Treating Mucosal Tissue Disorders

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606903A (en) 1944-03-29 1952-08-12 Physiological Chemicals Compan Ascorbic acid addition compound of sulfathiazole
US5070085A (en) 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US4968716A (en) 1987-04-10 1990-11-06 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
US4861783A (en) 1988-04-26 1989-08-29 E. I. Du Pont De Nemours And Company 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
US5304724A (en) 1988-09-09 1994-04-19 Entravision, Inc. Tissue irrigating solution
US5238683A (en) 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
ES2092539T3 (es) 1991-01-10 1996-12-01 Transcend Therapeutics Inc Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.
US6764693B1 (en) 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5626883A (en) 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
EP0938331B1 (en) 1996-11-01 2002-12-18 XOMA Technology Ltd. Therapeutic uses of bpi protein products in cystic fibrosis patients
EP0957901B1 (en) 1996-12-31 2009-11-18 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
US6896899B2 (en) 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US5906811A (en) 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5829449A (en) 1997-09-19 1998-11-03 Thione International, Inc. Smoking products containing antioxidants
US6415798B1 (en) 1997-09-19 2002-07-09 Thione International, Inc. Antioxidants to neutralize tobacco free radicals
US6470894B2 (en) 1997-09-19 2002-10-29 Thione International, Inc. Glutathione, green tea, grape seed extract to neutralize tobacco free radicals
US6228347B1 (en) 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
CA2339473A1 (en) 1998-08-04 2000-02-17 John V. Kosbab Nutrient and therapeutic compositions for the treatment of cancer
US6312734B1 (en) 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
DE19935763B4 (de) 1999-07-27 2006-03-02 Jenning, Volkhard, Dr. Zusammensetzung eines Redoxsystems zur Stabilisierung von Retinoiden in Präparaten zur äußerlichen Anwendung
US7045152B2 (en) 1999-09-08 2006-05-16 Duke University Treating pulmonary disorders with gaseous agent causing repletion of GSNO
US20020037855A1 (en) 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
EP1282416A2 (en) 2000-05-19 2003-02-12 Progenics Pharmaceuticals, Inc. Dehydroascorbic acid formulations and uses thereof
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
US6485950B1 (en) 2000-07-14 2002-11-26 Council Of Scientific And Industrial Research Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions
DE60141703D1 (de) 2000-10-16 2010-05-12 Univ Duke Therapeutische anwendung von zerstäubtem s-nitrosoglutathion bei zystischer fibrose
US20020165207A1 (en) 2001-05-02 2002-11-07 Richard Rosenbloom Compositions and methods for the treatment of diabetic neuropathy
WO2002053161A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
WO2002087508A2 (en) 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
WO2003051313A2 (en) 2001-12-18 2003-06-26 Brassica Foundation For Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
AUPS019802A0 (en) 2002-01-31 2002-02-21 Chemstop Pty Ltd Nutrient formulation
US20040229815A1 (en) 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
EP1691614B1 (en) 2003-12-04 2013-02-13 University Of Iowa Research Foundation Gallium inhibits biofilm formation
US20050271726A1 (en) 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
DE102004035113A1 (de) 2004-07-20 2006-02-16 Degussa Ag alpha-Liponsäure enthaltende Zusammensetzung bei cystischer Fibrose
JP5112876B2 (ja) 2004-11-07 2013-01-09 エフ． ギルフォード ティモシー 還元型グルタチオン経口投与のためのリポソーム処方物
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
CA2587883A1 (en) 2004-11-17 2006-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusale M Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma
US8703198B2 (en) 2005-03-02 2014-04-22 Aquatrove Biosciences Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof
EP1868430B1 (en) 2005-04-12 2015-07-08 Cleo Cosmetic and Pharmaceutical Co., LLC Composition and method for in vitro preservation of corneal tissues
US20060258599A1 (en) 2005-04-27 2006-11-16 Melanie Childers Methods and composition for the treatment of cystic fibrosis and related illnesses
WO2006125262A1 (en) 2005-05-24 2006-11-30 Environmental Biotechnology Crc Pty Limited Methods and compositions for regulating biofilm development
WO2007024876A2 (en) 2005-08-24 2007-03-01 The Board Of Trustees Of Leland Stanford Junior University Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis
US9333260B2 (en) 2006-05-10 2016-05-10 Laclede, Inc. Compositions and methods for enzymatic treatment of lung disorders
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
US20100310541A1 (en) 2007-05-25 2010-12-09 Ironwood Pharmaceuticals, Inc. Compositions and Methods for Reducing the Toxicity of Certain Toxins
WO2009001884A1 (ja) 2007-06-26 2008-12-31 Kyowa Hakko Bio Co., Ltd. 酸化型グルタチオン錠
JP2011026204A (ja) 2007-11-26 2011-02-10 Rei Furukawa タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
US9289462B2 (en) 2008-09-17 2016-03-22 Terry Gage Method for medical treatment utilizing glutathione
FR2941374B1 (fr) 2009-01-28 2011-03-11 Alaxia Utilisation d'une association synergique d'ions hypothiocyanites et/ou hypohalites et de lactoferrine pour la preparation pour le traitement de la mucoviscidose
US20120093947A1 (en) 2009-02-27 2012-04-19 United States Department Of Veterans Affairs Method of treating reactive airway disease
GB0908174D0 (en) 2009-05-13 2009-06-24 Isis Innovation Steroid containing composition and uses thereof
CN101987195B (zh) 2009-08-06 2012-07-18 重庆市力扬医药开发有限公司 经口腔粘膜吸收的还原型谷胱甘肽药物
IT1401504B1 (it) 2010-08-02 2013-07-26 Cattarini Mastelli Composizione comprendente glutatione reduttasi e glutatione ossidato
WO2012027603A2 (en) 2010-08-26 2012-03-01 Clarity Products, Limited Liability Company Therapeutic consumable compositions for reduction of facial flush effect incident to alcohol consumption in persons with deficient activity of the aldehyde dehydrogenase gene-aldh2
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
CN102100904B (zh) 2011-01-25 2013-04-24 成都卓阳生物科技有限公司 还原型谷胱甘肽经皮吸收制剂及其制备方法
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US20130084336A1 (en) 2011-06-27 2013-04-04 Albert Einstein College Of Medicine Of Yeshiva University Enhanced nitric oxide delivery and uses thereof
CN102329370B (zh) 2011-09-22 2015-07-22 山东金城医药化工股份有限公司 还原型谷胱甘肽单钠盐的制备方法
US20140234397A1 (en) 2013-02-15 2014-08-21 Lou Ann Brown Treatment of klebsiella pneumoniae with liposomally formulated glutathione
US9913801B2 (en) 2013-02-15 2018-03-13 Your Energy Systems, LLC Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione
ITPD20130052A1 (it) 2013-03-01 2014-09-02 Enologica Vason S P A Procedimento di vinificazione e prodotto per uso enologico atto ad essere utilizzato in detto procedimento di vinificazione
WO2016037166A1 (en) 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
WO2016067283A1 (en) 2014-10-30 2016-05-06 Rice Howard Virucidal compositions comprising tannins for nasal and pulmonary administration
WO2016088116A1 (en) 2014-12-05 2016-06-09 University Health Network Use of antioxidants as radio-protective agents
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
AU2017298202A1 (en) 2016-07-16 2019-02-07 Lauranell Harrison Burch Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
KR20230117644A (ko) * 2016-11-17 2023-08-08 레노비온, 아이엔씨. 글루타티온 조성물에 의한 호흡기 질환 및 감염 치료
ES3008699T3 (en) * 2017-11-17 2025-03-24 Renovion Inc Stable ascorbic acid compositions and methods of using the same
MX2020005310A (es) 2017-11-21 2020-10-08 Medoncare Pharmaceutical Co Ltd Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo.
EA202091396A1 (ru) 2017-12-07 2020-09-02 РИВЕН АйПи ХОЛДКО ЭлЭлСи Композиции и способы лечения метаболических состояний
CA3117213A1 (en) 2018-10-23 2020-04-30 George Edward Hoag Composition and method for treating the lungs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002004A1 (en) 1999-07-02 2001-01-11 Lee Hibahl Peritoneal dialysis solution containing antioxidant for treating renal failure
US20100311837A1 (en) 2008-02-05 2010-12-09 Kyowa Hakko Bio Co., Ltd. Method for improving storage stability of glutathione
US20150010654A1 (en) 2012-10-29 2015-01-08 The University Of North Carolina At Chapel Hill Methods and Compositions for Treating Mucosal Tissue Disorders

Also Published As

Publication number Publication date
EP3710036A4 (en) 2021-07-21
EP4473976A3 (en) 2025-03-12
MX2020005087A (es) 2020-08-13
HRP20241746T1 (hr) 2025-02-28
LT3710036T (lt) 2025-01-27
HUE069510T2 (hu) 2025-03-28
US20230144527A1 (en) 2023-05-11
PT3710036T (pt) 2025-01-22
CN111615395A (zh) 2020-09-01
US11497786B2 (en) 2022-11-15
AU2018367674A1 (en) 2020-06-04
CN111615395B (zh) 2024-08-06
JP7617179B2 (ja) 2025-01-17
AU2018367674B2 (en) 2025-02-27
KR102731292B1 (ko) 2024-11-18
RU2020117840A3 (enExample) 2022-04-22
IL274635B1 (en) 2024-07-01
DK3710036T3 (da) 2025-01-13
JP2023110019A (ja) 2023-08-08
US11890315B2 (en) 2024-02-06
IL274635B2 (en) 2024-11-01
SI3710036T1 (sl) 2025-03-31
IL274635A (en) 2020-06-30
US20200397849A1 (en) 2020-12-24
US20250295726A1 (en) 2025-09-25
FI3710036T3 (fi) 2024-12-27
EP3710036A1 (en) 2020-09-23
RU2020117840A (ru) 2021-12-17
MX2023010248A (es) 2023-09-15
CA3082900A1 (en) 2019-05-23
PH12020550645A1 (en) 2021-04-19
PL3710036T3 (pl) 2025-02-24
WO2019099946A1 (en) 2019-05-23
SG11202004540QA (en) 2020-06-29
JP2021503497A (ja) 2021-02-12
ES3008699T3 (en) 2025-03-24
EP3710036B1 (en) 2024-10-02
US12350307B2 (en) 2025-07-08
BR112020009910A2 (pt) 2020-11-03
AU2025200818A1 (en) 2025-02-27
US20240131109A1 (en) 2024-04-25
KR20200089702A (ko) 2020-07-27
EP4473976A2 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
JP7339955B2 (ja) 安定したアスコルビン酸組成物およびそれを使用する方法
Stockley Bronchiectasis—new therapeutic approaches based on pathogenesis
Barclay et al. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis
US6702998B2 (en) Methods and devices for treating lung dysfunction
CN102724983A (zh) 雾化左氧氟沙星治疗囊性纤维化的用途
US20100330061A1 (en) Methods and Devices for Treating Lung Dysfunction
CN110198728A (zh) 用谷胱甘肽组合物治疗呼吸道疾病和感染
RU2799046C2 (ru) Стабильные композиции аскорбиновой кислоты и способы их применения
CN110352053B (zh) 用于细菌感染的n-乙酰半胱氨酸和多黏菌素e的组合
HK40037040A (en) Stable ascorbic acid compositions and methods of using the same
HK40120872A (en) Stable ascorbic acid compositions and methods of using the same
HK40037040B (zh) 稳定的抗坏血酸组合物及其使用方法
US11918552B2 (en) N-acetylcysteine for use as antibacterial agent
HK40014103A (en) Treatment of respiratory tract diseases and infections with glutathione compositions
RU2464017C2 (ru) Способ лечения хронической обструктивной болезни легких с бронхоэктазами

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200615

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230825

R150 Certificate of patent or registration of utility model

Ref document number: 7339955

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150